Acadia Pharmaceuticals Inc. Revenue 2009–2025
Acadia Pharmaceuticals Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Acadia Pharmaceuticals Inc. revenue for the quarter ending March 31, 2026 was 268.1 M, a 9.72% increase year-over-year.
- Acadia Pharmaceuticals Inc. revenue for the twelve months ending March 31, 2026 was 1.1 B, a 16.01% increase year-over-year.
- Acadia Pharmaceuticals Inc. annual revenue for 2025 was 1.1 B, a 11.87% increase from 2024.
- Acadia Pharmaceuticals Inc. annual revenue for 2024 was 957.8 M, a 31.85% increase from 2023.
- Acadia Pharmaceuticals Inc. annual revenue for 2023 was 726.4 M, a 40.45% increase from 2022.
- Acadia Pharmaceuticals Inc. annual revenue for 2022 was 517.2 M.
Acadia Pharmaceuticals Inc. (ACAD) — Frequently Asked Questions
Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded US company. It has a market capitalization of $3.61B. In fiscal 2025 it reported revenue of $1.07B and net income of $391M. Explore ACAD's stock price, financial statements, earnings history, margins and key ratios below.
What is Acadia Pharmaceuticals Inc.'s market cap?
Acadia Pharmaceuticals Inc. (ACAD) has a market capitalization of $3.61B.
What is the ACAD stock price?
ACAD trades at $21.25 (-2.70% on the day).
How much revenue does Acadia Pharmaceuticals Inc. make?
Acadia Pharmaceuticals Inc. reported revenue of $1.07B in fiscal 2025.
Is ACAD profitable?
In fiscal 2025, Acadia Pharmaceuticals Inc. reported net income of $391M.